| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9956231 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US10064875 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US10588914 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9855334 | PRIMUS PHARMS | Topical compositions comprising a corticosteroid |
Mar, 2035
(10 years from now) | |
Impoyz is owned by Primus Pharms.
Impoyz contains Clobetasol Propionate.
Impoyz has a total of 4 drug patents out of which 0 drug patents have expired.
Impoyz was authorised for market use on 28 November, 2017.
Impoyz is available in cream;topical dosage forms.
Impoyz can be used as plaque psoriasis, twice daily topical treatment of moderate to severe plaque psoriasis., treatment of moderate to severe plaque psoriasis in patients 18 years of age or older.
The generics of Impoyz are possible to be released after 11 March, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 28, 2020 |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: Plaque psoriasis; Twice daily topical treatment of moderate to severe plaque psoriasis.; Treatment of moderate to severe plaque psoriasis in patients 18 years of age or older
Dosage: CREAM;TOPICAL
IMPOYZ family patents
